Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.57, $0.29 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $243.8 million versus the consensus estimate of $239.23 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.